June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Optical Coherence Tomography Signs of Early Atrophy in Age-related Macular Degeneration: Inter-Reader Agreement
Author Affiliations & Notes
  • Steffen Schmitz-Valckenberg
    Ophthalmology and Visual Sciences, University of Utah Health, Salt Lake City, Utah, United States
    Ophthalmology, Rheinische Friedrich-Wilhelms-Universitat Bonn, Bonn, Nordrhein-Westfalen, Germany
  • Zhichao Wu
    Centre for Eye Research Australia, University of Melbourne, Melbourne, Victoria, Australia
  • Maximilian Pfau
    Ophthalmic Genetics and Visual Function Branch, National Eye Institute, Bethesda, Maryland, United States
    Ophthalmology, Rheinische Friedrich-Wilhelms-Universitat Bonn, Bonn, Nordrhein-Westfalen, Germany
  • Barbara Blodi
    Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, Wisconsin, United States
  • Frank G Holz
    Ophthalmology, Rheinische Friedrich-Wilhelms-Universitat Bonn, Bonn, Nordrhein-Westfalen, Germany
  • Petrus Chang
    Ophthalmology, Rheinische Friedrich-Wilhelms-Universitat Bonn, Bonn, Nordrhein-Westfalen, Germany
  • Glenn J Jaffe
    Ophthalmology, Duke University, Durham, North Carolina, United States
  • Sandra Liakopoulos
    Klinikum der Universitat zu Koln Zentrum fur Augenheilkunde, Koln, Nordrhein-Westfalen, Germany
  • Srinivas R Sadda
    Doheny Eye Institute, University of California Los Angeles, Los Angeles, California, United States
  • Giovanni Staurenghi
    Luigi Sacco, Universita degli Studi di Milano, Milano, Lombardia, Italy
  • Robyn H Guymer
    Centre for Eye Research Australia, University of Melbourne, Melbourne, Victoria, Australia
  • Footnotes
    Commercial Relationships   Steffen Schmitz-Valckenberg, Acucela (F), Allergan (F), Allergan (C), Apellis (C), Bayer (F), Bioeq (F), Bioeq/Formycon (C), Carl Zeiss MediTec (F), Carl Zeiss MediTec (R), Centervue (F), Galimedix (C), Heidelberg Engineering (F), Katairo (F), Novartis (C), Novartis (R), Novartis (F), Optos (F), Oxurion (C), Roche (F), Roche (R); Zhichao Wu, None; Maximilian Pfau, Carl Zeiss MediTec (F), Centervue (F), Heidelberg Engineering (F), Optos (F); Barbara Blodi, None; Frank Holz, Acucela (F), Acucela (R), Allergan (F), Allergan (C), Apellis (C), Apellis (R), Bayer (C), Bayer (F), Bayer (R), Bioeq/Formycon (C), Bioeq/Formycon (F), Boehringer-Ingelheim (C), Centervue (F), Ellex (R), Geuder (C), Grayburg Vision (C), Grayburg Vision (R), Heidelberg Engeering (C), Heidelberg Engineering (F), Heidelberg Engineering (R), IvericBIO (C), Roche/Genentech (C), Roche/Genentech (F), Roche/Genentech (R); Petrus Chang, Carl Zeiss MediTec (F), Centervue (F), Heidelberg Engineering (F), Optos (F); Glenn Jaffe, Allegro (C), Iveric (C), Novartis (C), Regeneron (C); Sandra Liakopoulos, Allergan (R), Bayer (C), Bayer (R), Heidelberg Engineering (R), Novartis (C), Novartis (F), Novartis (R), Santhera (R), Zeiss (R); Srinivas Sadda, 4DMT (C), 4DMT (R), Allergan (R), Allergan (C), Amgen (R), Amgen (C), Bayer (R), Carl Zeiss MediTec (F), Carl Zeiss MediTec (R), Centervue (F), Centervue (R), Heidelberg Engineering (F), Nidek (F), Nidek (R), Novartis (C), Novartis (R), Optos (F), Oxurion (C), Oxurion (R), Regeneron (C), Regeneron (R), Roche/Genentech (C), Roche/Genentech (R), Topcon (F), Topcon (R); Giovanni Staurenghi, Alcon (R), Allergan (R), Bayer (C), Bayer (R), Boehringer Ingelheim (R), Carl Zeiss Meditec (C), Carl Zeiss Meditec (R), Carl Zeiss MediTec (F), Centervue (C), Centervue (F), Centervue (R), Heidelberg Engineering (C), Heidelberg Engineering (R), Nidek (F), Novartis (F), Novartis (C), Novartis (R), Optos (F), Optos (R), Optovue (F); Robyn Guymer, Apellis (C), Bayer (C), Genentech/Roche (C), Novartis (C)
  • Footnotes
    Support  Supported in part by an Unrestricted Grant from Research to Prevent Blindness, New York, NY, to the Department of Ophthalmology & Visual Sciences, University of Utah, Federal Ministry of Education and Research of Germany (BMBF), Scholarship FKZ 13N10349 and a National Health & Medical Research Council of Australia fellowship grant no.: GNT1103013 [RHG], the German Research Foundation (DFG) grant no.: PF950/1-1 [MP]
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 1936. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Steffen Schmitz-Valckenberg, Zhichao Wu, Maximilian Pfau, Barbara Blodi, Frank G Holz, Petrus Chang, Glenn J Jaffe, Sandra Liakopoulos, Srinivas R Sadda, Giovanni Staurenghi, Robyn H Guymer; Optical Coherence Tomography Signs of Early Atrophy in Age-related Macular Degeneration: Inter-Reader Agreement. Invest. Ophthalmol. Vis. Sci. 2021;62(8):1936.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To determine the inter-reader agreement for structural features related to incomplete and complete retinal pigment epithelium and outer retinal atrophy (iRORA and cRORA respectively) in age-related macular degeneration (AMD).

Methods : Following formal training (reviewing literature, performing a pre-test twice and undergoing a web-based tutorial), readers qualitatively assessed 60 optical coherence tomography (OCT) B-scans from 60 eyes with AMD for nine individual features associated with early atrophy and performed seven different annotations to quantify the spatial extent of OCT features within regions-of-interests. Cases were selected to depict the entire spectrum of findings that may be observed in dry AMD eyes with and without atrophy. Inter-reader agreement based on kappa coefficients (κ) and smallest real difference (SRD) was assessed.

Results : Slight to substantial inter-reader agreement was observed for assessment of individual features associated with atrophy (κ=0.19–0.70), with lowest and highest agreement being for outer nuclear layer thinning and inner nuclear layer (INL) subsidence, respectively. The lowest SRD for horizontal annotations was observed for the zone of choroidal hypertransmission (±190.8µm). Using the qualitative and quantitative gradings to derive atrophic features, there was moderate agreement for a two-category classification of the presence or absence of at least iRORA (κ=0.53), and substantial agreement for the presence or absence of cRORA (κ=0.62). There was moderate agreement for a three-category classification of no atrophy, iRORA and cRORA (κ=0.52). Exploratory analyses suggested a significantly higher level of agreement for a three-category classification using (i) no atrophy, (ii) presence of INL and outer plexiform layer subsidence, or a hyporeflective wedge-shaped band as a less severe atrophic grade and (iii) the latter plus an additional requirement of choroidal hypertransmission ≥250µm for a more severe atrophic grade (κ=0.68; P=0.004).

Conclusions : While current definitions of iRORA and cRORA allow for a consistent and robust assessment of early atrophy, a refined combination of individual features improved inter-reader agreement. This evaluation represents an important step towards a more detailed classification system for atrophic AMD and helps to inform the design and analysis of future early interventional clinical trials in AMD.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×